A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)

This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin

Inclusion Criteria:

• Males and females at least 18 years of age who have confirmed diagnosis of Non-small Cell Lung Cancer
• Patients with no systemic prior systemic treatment for lung cancer except patients at least 12 months from prior adjuvant therapy
• Adequate bone marrow,kidney and liver function
• Must be recovered and at least 4 weeks from major surgery or radiation
• ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1
• Men and women must agree to use birth control during the study
• Women able to have children must have a negative pregnancy test 14 days before study enrollment

Exclusion Criteria:

• Patients with prior treatment with other investigational agents less than 4 weeks before study enrollment
• Pregnant or nursing female patients
• Patients who are HIV positive
• Patients who have Hepatitis A, B, or C
• Patients unable to take study medication by mouth
• Patients with untreated brain cancer
• Patient eligible for treatment with bevacizumab and for whom bevacizumab is available